Immunome Notifies Availability of Press Release - IMNM News | RalliesImmunome Notifies Availability of Press Release
I
IMNM• Press release on first patient dosed in IM-3050 trial
- Immunome published a release announcing first patient dosed in a Phase 1, first-in-human trial of IM-3050 in FAP-expressing advanced solid tumors.
- IM-3050 is a FAP-targeted radioligand therapy designed to deliver lutetium-177 to FAP-expressing cells.
- Open-label, multicenter study will assess safety, tolerability, dosimetry, pharmacokinetics, preliminary anti-tumor activity.
- Dose-escalation aims to set maximum tolerated dose or recommended expansion dose; expansion to further evaluate safety at that level.
- Release posted at https://immunome.com/.
•
